Comprehensive HIV and Harm Prevention Via Telehealth
Recruiting
Comprehensive HIV and Harm Prevention Via Telehealth: CHARIOT, a Randomized Controlled Trial
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * age 18 or older * able to speak English or Spanish * willing and able to sign informed consent, provide locator information and medical records release * non-reactive result on rapid HIV test * use of SSP to exchange syringes 2 times in the past 3 months * planning to stay in the area for 12 months Exclusion Criteria: * reactive HIV test * currently on medications for opioid use disorder (MOUD) by urine drug screen * currently on PrEP by self-report * Principal or site investigator discretion * currently in prison or jail * current enrollment in Clinical Trials Network 121 * receipt of tele-harm reduction in previous 3 months * signs or symptoms of acute HIV infection
About the study
The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.
What is being tested
- Comprehensive Tele-harm Reduction (behavioral)
- Off-site Linkage to HIV Prevention (behavioral)
Sponsor: University of Miami · Participants: 350 · Started: Oct 7, 2024
Contact the study team
- Hansel Tookes, MD · Phone: 3052431615
Official record on ClinicalTrials.gov — NCT05897099
Locations in the U.S.
| Florida | IDEA Miami, Miami IDEA Syringe Services Program, Miami (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.